National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Everolimus (Votubia®) is indicated for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC.

Rapid Review

Commenced Completed Outcome
19/04/2017 26/04/2017 Full Pharmacoeconomic Evaluation Recommended

The company do not plan to submit a HTA dossier to the NCPE therefore the cost effectiveness of the technology cannot be proven.